Alnylam Pharmaceuticals
ALNY
#689
Rank
โ‚น3.501 T
Marketcap
โ‚น26,227
Share price
-1.64%
Change (1 day)
-2.19%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2026 (TTM): โ‚น346.28

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is โ‚น357.43. In 2025 the company made an earnings per share (EPS) of โ‚น169.76.

EPS history for Alnylam Pharmaceuticals from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)โ‚น346.28103.98%
2025โ‚น169.76
2023-โ‚น332.91-62%
2022-โ‚น876.1429.03%
2021-โ‚น679.03-3.36%
2020-โ‚น702.61-8.48%
2019-โ‚น767.687.67%
2018-โ‚น712.9839.74%
2017-โ‚น510.2212.94%
2016-โ‚น451.7438.84%
2015-โ‚น325.37-32.88%
2014-โ‚น484.75259.44%
2013-โ‚น134.86-31.25%
2012-โ‚น196.16

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
โ‚น662.06 85.22%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
โ‚น241.40-32.46%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
โ‚น4,011 1,022.16%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-โ‚น784.66-319.53%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-โ‚น68.85-119.26%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-โ‚น22.63-106.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
โ‚น129.20-63.85%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
โ‚น33.01-90.77%๐Ÿ‡บ๐Ÿ‡ธ USA